Publications by authors named "Zamira Merzhoeva"

9 Publications

  • Page 1 of 1

A 61-Year-Old Woman With Insidious Dyspnea and Diffuse Cystic Lung Disease.

Chest 2021 Aug;160(2):e199-e203

Pulmonology Scientific Research Institute, Federal Medical and Biological Agency of Russian Federation, Moscow, Russia.

A 61-year-old woman, an ex-smoker with a 10 pack year smoking history, was referred to our clinic for the evaluation of insidious dyspnea and diffuse, bilateral infiltrates on a chest radiograph. She reported that she had been experiencing dyspnea on exertion and dry cough for the past 1.5 years. She denied fevers, chills, hemoptysis, or weight loss. Aside from a smoking history, there were no comorbidities or environmental exposures. She had no family history of lung diseases or other disorders. She worked as a school teacher and had no occupational exposures. There were no pets in the home and no prior occupational exposures.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chest.2021.02.044DOI Listing
August 2021

N-acetylcysteine for the treatment of COVID-19 among hospitalized patients.

J Infect 2021 Jul 10. Epub 2021 Jul 10.

Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinf.2021.07.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271031PMC
July 2021

Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study.

Cytokine 2021 10 3;146:155627. Epub 2021 Jul 3.

International School 'Medicine of the Future', I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.

Background: One of the main pathophysiological mechanisms underlying the severe course of COVID-19 is the hyper-inflammatory syndrome associated with progressive damage of lung tissue and multi-organ dysfunction. IL-17 has been suggested to be involved in hyper-inflammatory syndrome.

Objective: To evaluate the efficacy and safety of the IL-17 inhibitor netakimab in patients with severe COVID-19.

Study Design: In our retrospective case-control study we evaluated the efficacy of netakimab in hospitalized patients with severe COVID-19 outside the intensive care unit (ICU). Patients in the experimental group were treated with standard of care therapy and netakimab at a dose of 120 mg subcutaneously.

Results: 171 patients with severe COVID-19 were enrolled in our study, and 88 of them received netakimab. On the 3 day of therapy, body temperature, SpO2/FiO2, NEWS2 score, and CRP improved significantly in the netakimab group compared to the control group. Other clinical outcomes such as transfer to ICU (11.4% vs 9.6%), need for mechanical ventilation (10.2% vs 9.6%), 28-day mortality (10.2% vs 8.4%), did not differ between the groups.

Conclusion: In hospitalized patients with severe COVID-19, anti-IL-17 therapy might mitigate the inflammatory response and improve oxygenation, but do not affect the need for mechanical ventilation and mortality.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2021.155627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253694PMC
October 2021

Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome.

Respir Med 2021 Aug-Sep;185:106489. Epub 2021 May 29.

Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.

Background: We have investigated the use of nebulized surfactant as a potential therapeutic option for the patients with coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS) undergoing non-invasive ventilation.

Methods: The patients were divided into 2 groups: surfactant (n = 33) and control (n = 32). The subjects in the surfactant group received the inhaled surfactant at daily dose of 150-300 mg. The oxygenation parameters and several clinical outcomes were analyzed.

Results: On the 5 day of therapy, PaO/FiO improved significantly in the surfactant group compared to the control group (184 (155-212) mmHg vs 150 (91-173) mmHg, p = 0.02). The inhaled surfactant significantly reduced the need for transfer of patients to intensive care units (24.2% vs 46.9%, p = 0.05) and invasive mechanical ventilation (18.2% vs 40.6%, p = 0.04). Even more, the nebulized surfactant shortened the length of non-invasive ventilation (7 (3-13) days vs 11 (5-22) days, p = 0.02) and time spent in hospital (18 (16-27) days vs 26 (21-31) days, p = 0.003) in patients suffering from COVID-19-linked ARDS.

Conclusions: Our preliminary data provided indications that inhaled surfactant therapy may represent a promising option for patients with COVID-19-associated ARDS. However, larger clinical trials are crucially needed.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2021.106489DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163691PMC
September 2021

Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale.

Int J Infect Dis 2021 Mar 13;104:108-110. Epub 2021 Jan 13.

I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. Electronic address:

Existing literature highlights the fact that patients with COVID-19 exhibit alterations in the coagulation process and are associated with respiratory and cardiovascular diseases, including acute respiratory distress syndrome and acute cor pulmonale. In this report, we describe the effects of systemic thrombolysis on acute cor pulmonale in a patient suffering from COVID-19. We demonstrated that systemic thrombolysis successfully improved the hemodynamics of our patient and resulted in a prominent reduction in hypercapnia, alveolar dead space, and ventilatory ratio.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijid.2020.12.043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833717PMC
March 2021

Noninvasive ventilation for acute hypoxemic respiratory failure in patients with COVID-19.

Am J Emerg Med 2021 Jan 1;39:154-157. Epub 2020 Oct 1.

Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.

Aim: Noninvasive ventilation (NIV) is known to reduce intubation in patients with acute hypoxemic respiratory failure (AHRF). We aimed to assess the outcomes of NIV application in COVID-19 patients with AHRF.

Materials & Methods: In this retrospective cohort study, patients with confirmed diagnosis of COVID-19 and AHRF receiving NIV in general wards were recruited from two university-affiliated hospitals. Demographic, clinical, and laboratory data were recorded at admission. The failure of NIV was defined as intubation or death during the hospital stay.

Results: Between April 8 and June 10, 2020, 61 patients were enrolled into the final cohort. NIV was successful in 44 out of 61 patients (72.1%), 17 patients who failed NIV therapy were intubated, and among them 15 died. Overall mortality rate was 24.6%. Patients who failed NIV were older, and had higher respiratory rate, PaCO, D-dimer levels before NIV and higher minute ventilation and ventilatory ratio on the 1-st day of NIV. No healthcare workers were infected with SARS-CoV-2 during the study period.

Conclusions: NIV is feasible in patients with COVID-19 and AHRF outside the intensive care unit, and it can be considered as a valuable option for the management of AHRF in these patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajem.2020.09.075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527350PMC
January 2021
-->